A meaningful milestone just appeared on ClinicalTrials.gov for anyone following retatrutide — the investigational triple agonist that has generated more excitement in the obesity medicine community than perhaps any drug in the past decade. As of June 9, 2026, the TRIUMPH Phase 3 trial (NCT07357415) has closed enrollment, transitioning from actively recruiting to no longer accepting new participants. For the thousands of people on waitlists hoping this drug becomes available, that status change carries significant clinical and logistical implications worth unpacking carefully.
When a large-scale Phase 3 clinical trial closes enrollment, it signals that the sponsor — in this case Eli Lilly and Company — has successfully recruited its target number of participants. The trial does not stop; rather, it enters the follow-through phase in which enrolled participants continue receiving treatment and completing assessments on schedule. No new participants can join.
For retatrutide, commonly referred to as reta in patient communities, this is genuinely encouraging news. Enrollment delays are one of the most common reasons Phase 3 timelines slip. The fact that the TRIUMPH trial has reached its enrollment target and closed on schedule suggests the study is progressing without the kind of logistical setbacks that often push approval timelines back by years.
It is important to be clear about what this does not mean: enrollment closing is not the same as FDA approval, and retatrutide has not been approved by the FDA as of this writing. No New Drug Application (NDA) has been filed as of April 2026. The path from a closed Phase 3 enrollment to a patient walking out of a clinic with a prescription is still a multi-year process involving data collection, peer-reviewed publication, NDA submission, and FDA review.
The TRIUMPH Phase 3 trial is a study of retatrutide (LY3437943) in participants without type 2 diabetes who have obesity or overweight with at least one weight-related comorbidity. This eligibility profile closely mirrors the population studied in the Phase 2 trial published in the New England Journal of Medicine in 2023, which enrolled adults with a BMI of 30 kg/m² or higher, or 27 kg/m² or higher with a qualifying condition such as hypertension or dyslipidemia — and specifically excluded individuals with type 2 diabetes.
Understanding who qualified for the trial matters for patients trying to contextualize the efficacy data. The Phase 2 results were already striking: at the 12mg dose over 48 weeks, mean weight loss reached approximately 24.2% compared to roughly 2.1% with placebo. At the 8mg dose, 70% of participants achieved at least 20% body weight reduction. These are figures that would have seemed implausible in obesity pharmacotherapy just five years ago.
The Phase 3 TRIUMPH-4 data, released via Eli Lilly press release in December 2025, raised the bar further. At the 12mg dose over 68 weeks, mean weight loss reached 28.7% — the highest ever recorded in a Phase 3 obesity trial. The table below places this in clinical context alongside other approved agents.
| Drug | Mechanism | Trial | Duration | Mean Weight Loss (Top Dose) |
|---|---|---|---|---|
| Semaglutide 2.4mg | GLP-1 agonist | STEP-1 | 68 weeks | ~14.9% |
| Tirzepatide 15mg | GLP-1 / GIP dual agonist | SURMOUNT-1 | 72 weeks | ~20.9% |
| Retatrutide 12mg | GLP-1 / GIP / glucagon triple agonist | TRIUMPH-4 (Phase 3) | 68 weeks | ~28.7% |
Retatrutide's unique pharmacology as a triple agonist — acting simultaneously on GLP-1, GIP, and glucagon receptors — is what differentiates it mechanistically from everything currently on the market. The glucagon receptor component, in particular, appears to drive additional energy expenditure and fat oxidation beyond what dual agonists achieve. Patients in online communities sometimes call this the "triple G" effect, a shorthand that captures its three-receptor action, though the formal designation remains triple agonist.
Beyond the scale on the scale, the Phase 2 data showed meaningful improvements in fasting triglycerides (down approximately 34% at 12mg by week 24) and LDL cholesterol (down approximately 15–17% at 8mg), suggesting cardiometabolic benefits that extend well past weight reduction alone. Quality-of-life scores on the SF-36v2 also improved across all active dose groups — a finding that resonates for patients who experience the relentless cognitive burden of food noise as one of obesity's most exhausting symptoms.
The TRIUMPH-4 titration schedule is worth noting: participants started at 2mg for the first four weeks, escalating every four weeks through 4mg, 6mg, and 9mg before reaching the 12mg maintenance dose at week 17. This gradual escalation is designed to improve tolerability. Gastrointestinal side effects — nausea, diarrhea, and vomiting — remain the most commonly reported adverse events and are dose-dependent, typically peaking during the titration phase. Dysesthesia (abnormal skin sensations) was reported in 20.9% of participants at the 12mg dose in TRIUMPH-4, compared to 0.7% with placebo, a figure that warrants attention and candid discussion between patients and their clinicians.
According to ClinicalTrials.gov, the primary completion date for the TRIUMPH Phase 3 trial (NCT07357415) is October 2028. Primary completion refers to the date by which the last participant is expected to provide the primary outcome data — in this case, percent change in body weight at the designated primary endpoint.
Following primary completion, Eli Lilly would need to compile the full clinical dataset, complete regulatory-quality analyses, and submit a New Drug Application to the FDA. The FDA's standard review clock runs approximately 12 months from NDA acceptance, with priority review potentially shortening that window. As of April 2026, no NDA has been filed. A realistic, optimistic scenario places potential FDA approval no earlier than late 2029 or 2030, depending on submission timing and review pathway — though those figures are estimates, not confirmed timelines.
The peer-reviewed Phase 3 publication is also still pending as of April 2026. Full publication will be essential for the medical community to evaluate the complete safety and efficacy dataset, particularly longer-term tolerability data and subgroup analyses.
For patients who have been tracking reta carefully, the closed-enrollment status is a signal that the clinical machinery is running. The data are being generated. The timeline, while still measured in years, is moving forward.
If retatrutide is something you are watching closely, joining the glp3md waitlist is a practical way to stay current as trial data, regulatory filings, and availability news evolve. The waitlist exists to keep informed patients connected to accurate, clinically grounded information — not to promise any specific treatment or medication access. Retatrutide is not FDA-approved, and no guarantee of future prescriptions or availability can be made. To add your name and stay informed as the TRIUMPH data matures toward potential approval, visit https://www.glp3md.com.
Join the waitlist for priority access to a prescribing physician when retatrutide receives FDA approval.
Join the WaitlistThis article is for educational purposes only and does not constitute medical advice. Retatrutide is an investigational drug and is not FDA approved as of publication. Clinical data referenced is from publicly available trial publications. Consult a qualified healthcare provider before making any treatment decisions.